694 reports of this reaction
4.2% of all NEVIRAPINE reports
#4 most reported adverse reaction
VIRAL MUTATION IDENTIFIED is the #4 most commonly reported adverse reaction for NEVIRAPINE, manufactured by Amneal Pharmaceuticals LLC. There are 694 FDA adverse event reports linking NEVIRAPINE to VIRAL MUTATION IDENTIFIED. This represents approximately 4.2% of all 16,383 adverse event reports for this drug.
Patients taking NEVIRAPINE who experience viral mutation identified should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VIRAL MUTATION IDENTIFIED is moderately reported among NEVIRAPINE users, representing a notable but not dominant share of adverse events.
In addition to viral mutation identified, the following adverse reactions have been reported for NEVIRAPINE:
The following drugs have also been linked to viral mutation identified in FDA adverse event reports:
VIRAL MUTATION IDENTIFIED has been reported as an adverse event in 694 FDA reports for NEVIRAPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VIRAL MUTATION IDENTIFIED accounts for approximately 4.2% of all adverse event reports for NEVIRAPINE, making it a notable side effect.
If you experience viral mutation identified while taking NEVIRAPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.